United States Patent 6,258,830: Scope, Claims, and Landscape for Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate Gel Formulations
What is the claimed invention in US 6,258,830?
US 6,258,830 claims a stable topical gel intended to treat both acne and psoriasis using a specific synthetic retinoid and a defined set of formulation excipients designed to manage release and/or solubility.
Core active
- Synthetic retinoid: Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate
Core gel/excipient system (claim-limiting)
- Polysorbate 40: >0% to about 0.4 wt %
- Poloxamer 407:
- Claim 1: >0% to about 0.4 wt %, and optional (claim text: “optionally Poloxamer 407 present” while also stating the range)
- Claim 2: >0% (no explicit upper bound stated in the excerpt)
- Hexylene glycol: about 2 wt %
Functional requirement
The formulation must include the excipients in amounts that achieve a formulation performance function:
- Claim 1: control release of the synthetic retinoid from the gel to skin of a patient with acne or psoriasis.
- Claim 2: control solubility of the synthetic retinoid from the gel.
Clinical/indication scope
Both claims are for topical treatment of acne and psoriasis (same therapeutic framing in both claim 1 and claim 2).
What do Claims 1 and 2 cover, exactly?
Claim 1 (release control + optional Poloxamer)
A stable gel formulation comprising:
- Retinoid: Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate in an effective amount
- Polysorbate 40: >0% to about 0.4 wt %
- Poloxamer 407: >0% to about 0.4 wt %, but the claim text also states optionally present
- Hexylene glycol: about 2 wt %
- The excipient amounts of Polysorbate 40, hexylene glycol, and optionally Poloxamer 407 are present to control release of the retinoid to skin of a patient with acne or psoriasis.
Claim 1 claim-control points
- Active identity is fixed.
- Polysorbate 40 is tightly bounded (upper ~0.4 wt %).
- Hexylene glycol is fixed at ~2 wt %.
- Poloxamer 407 is bounded if present and is framed as optional.
- Performance function is release control, not merely stability.
Claim 2 (solubility control + Poloxamer mandatory if used)
A stable gel formulation comprising:
- Retinoid: Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate
- Polysorbate 40: >0% to about 0.4 wt %
- Poloxamer 407: >0% (upper bound not stated in the excerpt)
- Hexylene glycol: about 2 wt %
- Amounts of Polysorbate 40, hexylene glycol, and optionally Poloxamer 407 are present to control solubility of the retinoid from the gel.
Claim 2 claim-control points
- Active identity is fixed.
- Polysorbate 40 upper bound remains capped.
- Hexylene glycol is pinned at ~2 wt %.
- Poloxamer 407 is again tied to performance function and is described as optionally present in the functional clause, despite the earlier “present in amount greater than 0%” language in the excerpt.
What is the scope boundary for competitors? (practical claim map)
A. Literal “must-haves”
A product that potentially reads on the patent needs all of the following, as expressed in claim language:
- Same retinoid active
- Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate
- Topical gel dosage form presented as a stable gel
- Polysorbate 40
- Must be >0% and up to about 0.4 wt %
- Hexylene glycol
- Poloxamer 407 handling
- For Claim 1: optional in the functional clause; if included, it is >0% to about 0.4 wt %
- For Claim 2: includes language of “present in an amount greater than 0%” while the functional clause says “optionally Poloxamer 407”
B. Functional boundary (release vs solubility)
- A formulation designed and tested to control release is captured by Claim 1.
- A formulation designed and tested to control solubility is captured by Claim 2.
This matters because even if excipient quantities are similar, the claimed invention can hinge on how the system is formulated (and how it is framed in the infringement analysis).
C. Indication framing
The gel is claimed for topical treatment of acne and psoriasis. For infringement in the U.S., indication language often matters more for label use and marketing than for chemistry itself, but it still constrains the intended patient population in the claim.
How narrow or broad are these claims?
Narrow features that strongly constrain coverage
- Single, specific synthetic retinoid identity
- The claims do not cover “retinoids” generally.
- Excipient quantification
- Polysorbate 40 is bounded to an upper range of about 0.4 wt %
- Hexylene glycol is pinned to about 2 wt %
- Performance function
- Claim 1 requires release control; Claim 2 requires solubility control.
Potential breadth that remains
- “Effective amount” of retinoid
- The claim does not specify a numeric upper or lower bound for active load in the excerpt.
- “Stable gel formulation”
- “Stable” is usually supported by specification data, and can be fact-driven in infringement and validity.
- Polymer/gelling system not explicitly enumerated in the excerpt
- The claim terms cover “gel formulation” but do not, in the excerpt, specify the gelling polymer network. That leaves potential room for other polymers or gel matrices depending on the rest of the patent.
What does this mean for design-around strategy? (claim-reading logic)
A competitor seeking to avoid literal infringement would generally target one or more of the fixed claim constraints:
High-leverage design-around points
- Hexylene glycol deviation
- Claim requires about 2 wt %.
- Polysorbate 40 upper bound
- Claim requires >0% up to about 0.4 wt %.
- Retinoid identity
- Using a different retinoid (or a different ester/prodrug structure) would remove literal coverage.
- Poloxamer 407 approach
- Claim language ties it to performance and (in Claim 1) bounds it up to about 0.4 wt % if present.
Lower-leverage points
- Changing marketing or label indication may reduce practical enforcement risk but does not erase chemistry-based claim reading if the formulation matches the claim.
Patent landscape: where this fits relative to topical synthetic retinoid formulation IP
Given only the claim excerpt, the landscape can be analyzed at the level of technical claim themes and likely competitive overlap zones rather than enumerating specific cited patents or family members (not provided here).
1. The key IP theme is excipient-controlled delivery of a specific retinoid
This patent’s center of gravity is not a new active. It is a formulation system that stabilizes and tunes release/solubility using:
- Polysorbate 40 (surfactant)
- Hexylene glycol (co-solvent/humectant class excipient commonly used for stability and solubilization)
- Poloxamer 407 (surfactant/co-solubilizer with micellar behavior, depending on gel microstructure)
2. Competitor overlap is most likely in three zones
- Topical retinoid gels for acne and psoriasis indications
- Surfactant selection and concentration windows for retinoid solubilization
- Delivery control via excipient-driven release kinetics, including solubilizers and co-solvents
3. Enforcement posture for this type of claim
Formulation patents of this structure often get enforced against:
- Products using the same active with similar excipient quantities, or
- Products that are demonstrably formulated to achieve the claimed release/solubility behavior, with supporting label or technical data used to connect performance to claims.
Risk matrix for product development using similar actives
The following is a direct claim-reading matrix using the variables explicitly present in the claims.
| Variable |
Claim requirement (from excerpt) |
Risk if deviating |
| Active |
Must be Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate |
Removing the active identity is the strongest route to non-infringement |
| Polysorbate 40 |
>0% to about 0.4 wt % |
Using none or exceeding the upper limit breaks the literal range |
| Hexylene glycol |
about 2 wt % |
Using materially different concentration breaks the literal requirement |
| Poloxamer 407 |
optional in Claim 1 functional clause; >0% to about 0.4 wt % if present in Claim 1; Claim 2 text indicates >0% and ties function to “optionally Poloxamer 407” |
Omitting it or changing it beyond the functional/quantitative constraints can reduce literal risk |
| Performance |
Claim 1: control release; Claim 2: control solubility |
A formulation without performance mapping to release/solubility may avoid claim reading depending on evidence |
Claim construction pressure points (where disputes usually arise)
Even without the specification, formulation claims like these generate disputes in three main categories:
- “Stable gel formulation”
- Whether stability is measured under defined conditions
- Whether the accused product remains a “stable gel” in useable shelf-life terms
- “About” ranges
- “About 0.4 wt %” and “about 2 wt %” create tolerance issues
- Functional language
- Whether excipient roles truly “control release” (Claim 1) or “control solubility” (Claim 2) under relevant testing and formulation conditions
Key Takeaways
- US 6,258,830 claims a stable topical gel that treats acne and psoriasis using a single fixed synthetic retinoid: Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate.
- The formulation scope is tightly constrained by excipient windows: Polysorbate 40 (>0% to ~0.4 wt %) and hexylene glycol (~2 wt %), with Poloxamer 407 present in a limited window in Claim 1 and tied to solubility/release functions in Claim 2.
- The key differentiation between the two claims is functional intent: Claim 1 targets release control, while Claim 2 targets solubility control.
- From a design perspective, the highest-value non-infringement levers are: change the active identity, move hexylene glycol away from ~2 wt %, or move Polysorbate 40 outside >0% to ~0.4 wt %.
FAQs
1) Does US 6,258,830 claim any retinoid besides Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate?
No. The claims as given require that specific synthetic retinoid identity.
2) Are Polysorbate 40 and hexylene glycol mandatory?
Yes in the ranges stated: Polysorbate 40 must be present >0% and up to about 0.4 wt %, and hexylene glycol must be present at about 2 wt %.
3) Is Poloxamer 407 required?
Claim 1 treats Poloxamer 407 as optionally present in the functional clause; the excerpt also states a >0% to about 0.4 wt % range if included. Claim 2 includes language indicating >0% while also tying the functional requirement to “optionally Poloxamer 407” in the excerpt.
4) What is the difference between Claim 1 and Claim 2?
Claim 1 requires excipients in amounts to control release to skin. Claim 2 requires excipients in amounts to control solubility from the gel.
5) Does the patent cover treatment of acne and psoriasis?
Yes. The claims frame the gel as for topical treatment of both acne and psoriasis.
References
[1] U.S. Patent No. 6,258,830 (claims as provided in user prompt).
